title: Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task.
abstract: It is widely accepted that enduring parkinsonian symptoms are only evident if there are few remaining dopaminergic neurons in the substantia nigra and dopamine levels in the basal ganglia are very low [26,41]. In the present study, partial dopamine depletions were produced by infusing 6-OHDA bilaterally into the ventrolateral striatum as previously described [11,12,44]. Consistent with previous studies, behavioral deficits were detectable in rats with partial lesions with a simple fixed-ratio bar-pressing task. The present study demonstrated that these behavioral deficits were long-lasting, and that the sensitivity of this bar-pressing task could be increased by manipulating the level of difficulty of the task-higher fixed ratios were more sensitive to partial dopamine depletions. Deficits in rats with partial dopamine depletions could also be detected using non-automated neurological tests of parkinsonian symptoms developed for rats with severe unilateral dopamine depletions, but these deficits were transient and not as robust as those detected with the bar-pressing task. Oral Sinemet (L-DOPA:carbidopa) did not attenuate behavioral deficits related to partial dopamine depletions in this simple fixed-ratio bar-pressing task, but the present results suggest that Parkinson's patients might be identifiable earlier in the disease process, at a time when they could benefit from treatment with neuroprotective/neurotrophic agents. In addition, the results of the present study demonstrate that robust behavioral deficits may emerge with age. Mild dopamine depletions that were not detectable behaviorally at the time of the insult became clearly evident 10 months after the lesion with this bar-pressing task, and this may represent a more clinically relevant rodent model of Parkinson's disease.
authors.affiliation: Cyto Therapeutics, Providence, RI 02906, USA. MLINDER@CYTO.COM
authors.forename: M D
authors.initials: MD
authors.lastname: Lindner
authors.forename: M A
authors.initials: MA
authors.lastname: Plone
authors.forename: J M
authors.initials: JM
authors.lastname: Francis
authors.forename: T J
authors.initials: TJ
authors.lastname: Blaney
authors.forename: J D
authors.initials: JD
authors.lastname: Salamone
authors.forename: D F
authors.initials: DF
authors.lastname: Emerich
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001070:Appetitive Behavior / Q000187:drug effects / Q000502:physiology*; D001931:Brain Mapping; D002230:Carbidopa / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology*; D004292:Dominance, Cerebral / Q000187:drug effects / Q000502:physiology*; D004298:Dopamine / Q000502:physiology*; D004338:Drug Combinations; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D011939:Mental Recall / Q000187:drug effects / Q000502:physiology*; D009048:Motor Skills / Q000187:drug effects / Q000502:physiology; D016627:Oxidopamine / Q000494:pharmacology; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012055:Reinforcement Schedule
chemical_list: D000978:Antiparkinson Agents; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D016627:Oxidopamine; D002230:Carbidopa; D004298:Dopamine